These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 25614375)
1. Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer. Monsó E; Montuenga LM; Sánchez de Cos J; Villena C; Arch Bronconeumol; 2015 Sep; 51(9):462-7. PubMed ID: 25614375 [TBL] [Abstract][Full Text] [Related]
2. Validation of the 7th TNM classification for non-small cell lung cancer: a retrospective analysis on prognostic implications for operated node-negative cases. Bergman P; Brodin D; Lewensohn R; de Petris L Acta Oncol; 2013 Aug; 52(6):1189-94. PubMed ID: 23215828 [TBL] [Abstract][Full Text] [Related]
3. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308 [TBL] [Abstract][Full Text] [Related]
4. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913 [TBL] [Abstract][Full Text] [Related]
5. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843 [TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469 [TBL] [Abstract][Full Text] [Related]
7. DNA methylation markers and early recurrence in stage I lung cancer. Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602 [TBL] [Abstract][Full Text] [Related]
8. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P; J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556 [TBL] [Abstract][Full Text] [Related]
9. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980 [TBL] [Abstract][Full Text] [Related]
10. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors. Sánchez de Cos Escuín J; Abal Arca J; Melchor Íñiguez R; Miravet Sorribes L; Núñez Ares A; Hernández Hernández JR; García Arangüena L; Núñez Delgado M; Pavón Fernández MJ; Francisco Corral G; de Esteban Júlvez L; González Budiño MT; Abad Cavaco F; Ansótegui Barrera E; Andreo García F; Serra Mitjans M; Hernández Rodríguez H Lung Cancer; 2014 May; 84(2):182-9. PubMed ID: 24629637 [TBL] [Abstract][Full Text] [Related]
11. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826 [TBL] [Abstract][Full Text] [Related]
12. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699 [TBL] [Abstract][Full Text] [Related]
13. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724 [TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer staging: proposed revisions to the TNM system. Schneider BJ Cancer Imaging; 2008 Sep; 8(1):181-5. PubMed ID: 18824424 [TBL] [Abstract][Full Text] [Related]
15. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454 [TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310 [TBL] [Abstract][Full Text] [Related]
17. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. Rami-Porta R; Bolejack V; Giroux DJ; Chansky K; Crowley J; Asamura H; Goldstraw P; J Thorac Oncol; 2014 Nov; 9(11):1618-24. PubMed ID: 25436796 [TBL] [Abstract][Full Text] [Related]
18. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809 [TBL] [Abstract][Full Text] [Related]
20. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]